Abstract
This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.
| Original language | English |
|---|---|
| Pages (from-to) | 319-327 |
| Number of pages | 9 |
| Journal | Personalized Medicine |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 1 2018 |
Fingerprint
Cite this
The interference between oxaliplatin & anti-EGFR therapies : a different hypothesis to explain the 'unexplainable'. / Basso, Michele; Dadduzio, Vincenzo; Rossi, Sabrina; D'Argento, Ettore; Strippoli, Antonia; Di Salvatore, Mariantonietta; Orlandi, Armando; Zurlo, Valeria; Di Noia, Vincenzo; Barone, Carlo.
In: Personalized Medicine, Vol. 15, No. 4, 01.07.2018, p. 319-327.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The interference between oxaliplatin & anti-EGFR therapies
T2 - a different hypothesis to explain the 'unexplainable'
AU - Basso, Michele
AU - Dadduzio, Vincenzo
AU - Rossi, Sabrina
AU - D'Argento, Ettore
AU - Strippoli, Antonia
AU - Di Salvatore, Mariantonietta
AU - Orlandi, Armando
AU - Zurlo, Valeria
AU - Di Noia, Vincenzo
AU - Barone, Carlo
PY - 2018/7/1
Y1 - 2018/7/1
N2 - This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.
AB - This paper has been written because we have a differing idea concerning the suspected negative interference between oxaliplatin and anti-EGFR therapies in cancer patients. Several multicenter, randomized, controlled clinical trials investigated whether the efficacy of oxaliplatin-based chemotherapy is improved by the addition of anti-EGFR therapies in patients affected by KRAS wild-type advanced colorectal cancer. Results of these trials have produced puzzling findings, with some studies demonstrating improved survival and other studies showing no differences in overall survival between experimental and control arms. Moreover, a detrimental effect has been demonstrated in some settings. Nevertheless, the extent of this interaction remains uncertain. Some physicians proposed personal interpretations. This paper describes our hypothesis.
U2 - 10.2217/pme-2017-0082
DO - 10.2217/pme-2017-0082
M3 - Article
C2 - 29927360
VL - 15
SP - 319
EP - 327
JO - Personalized Medicine
JF - Personalized Medicine
SN - 1741-0541
IS - 4
ER -